A trial of tipapkinogene sovacivec [TG-4001] in combination with immune checkpoint inhibitors in patients with advanced HPV-induced cancer

Trial Profile

A trial of tipapkinogene sovacivec [TG-4001] in combination with immune checkpoint inhibitors in patients with advanced HPV-induced cancer

Planning
Phase of Trial: Phase II

Latest Information Update: 05 Sep 2016

At a glance

  • Drugs Tipapkinogene sovacivec (Primary) ; Immunomodulators
  • Indications Head and neck cancer; Human papillomavirus infections
  • Focus Therapeutic Use
  • Sponsors Transgene
  • Most Recent Events

    • 05 Sep 2016 According to a Transgene media release, this study is expected to begin in the second half of 2017.
    • 30 Mar 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top